Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
Abstract Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15104 |
| _version_ | 1797635937677606912 |
|---|---|
| author | Kosuke Masuda Yoshiaki Nagai Hikari Amari Hiroki Tahara Yuki Maeda Jun Shiihara Hiromitsu Ohta Masahiro Hiruta Yasuhiro Yamaguchi |
| author_facet | Kosuke Masuda Yoshiaki Nagai Hikari Amari Hiroki Tahara Yuki Maeda Jun Shiihara Hiromitsu Ohta Masahiro Hiruta Yasuhiro Yamaguchi |
| author_sort | Kosuke Masuda |
| collection | DOAJ |
| description | Abstract Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durvalumab for metastatic recurrence confined to the mediastinal lymph nodes. Three weeks later, multiple randomly distributed nodular shadows appeared on chest CT, and thoracoscopic lung biopsy led to the diagnosis of multiple pulmonary metastases. HPD may be suspected when multiple metastases appear in new organs early after the administration of ICIs. This phenomenon may occur not only with ICI monotherapy but also with the administration of ICIs after chemoradiotherapy. Therefore, patients who have received radiation therapy should also be given similar attention early after the administration of ICIs. |
| first_indexed | 2024-03-11T12:27:55Z |
| format | Article |
| id | doaj.art-e909103745de484da881f5fc0ee1eb6e |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-11T12:27:55Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-e909103745de484da881f5fc0ee1eb6e2023-11-06T07:15:22ZengWileyThoracic Cancer1759-77061759-77142023-11-0114313161316510.1111/1759-7714.15104Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case reportKosuke Masuda0Yoshiaki Nagai1Hikari Amari2Hiroki Tahara3Yuki Maeda4Jun Shiihara5Hiromitsu Ohta6Masahiro Hiruta7Yasuhiro Yamaguchi8Division of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanDepartment of Pathology Jichi Medical University Saitama Medical Center Saitama JapanDivision of Respiratory Medicine, Clinical Department of Internal Medicine Jichi Medical University Saitama Medical Center Saitama JapanAbstract Hyperprogressive disease (HPD) is a novel progressive pattern that occurs after immune checkpoint inhibitor (ICI) administration. Here, a 74‐year‐old woman who had undergone right lower lobectomy for lung cancer received curative chemoradiotherapy followed by consolidation therapy with durvalumab for metastatic recurrence confined to the mediastinal lymph nodes. Three weeks later, multiple randomly distributed nodular shadows appeared on chest CT, and thoracoscopic lung biopsy led to the diagnosis of multiple pulmonary metastases. HPD may be suspected when multiple metastases appear in new organs early after the administration of ICIs. This phenomenon may occur not only with ICI monotherapy but also with the administration of ICIs after chemoradiotherapy. Therefore, patients who have received radiation therapy should also be given similar attention early after the administration of ICIs.https://doi.org/10.1111/1759-7714.15104hyperprogressive diseaseimmune checkpoint inhibitorlung cancer |
| spellingShingle | Kosuke Masuda Yoshiaki Nagai Hikari Amari Hiroki Tahara Yuki Maeda Jun Shiihara Hiromitsu Ohta Masahiro Hiruta Yasuhiro Yamaguchi Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report Thoracic Cancer hyperprogressive disease immune checkpoint inhibitor lung cancer |
| title | Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report |
| title_full | Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report |
| title_fullStr | Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report |
| title_full_unstemmed | Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report |
| title_short | Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report |
| title_sort | hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy a case report |
| topic | hyperprogressive disease immune checkpoint inhibitor lung cancer |
| url | https://doi.org/10.1111/1759-7714.15104 |
| work_keys_str_mv | AT kosukemasuda hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT yoshiakinagai hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT hikariamari hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT hirokitahara hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT yukimaeda hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT junshiihara hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT hiromitsuohta hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT masahirohiruta hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport AT yasuhiroyamaguchi hyperprogressivediseaseinlungmetastaseswithouttargetlesionprogressionafterdurvalumabconsolidationtherapyacasereport |